Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges (2017 - 2026)

Amneal Pharmaceuticals' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 42.89% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $19.5 million (down 32.97% YoY), while the FY2025 annual figure was $22.4 million, down 22.91% from the prior year.
• Amortization of Deferred Charges was $3.9 million for Q1 2026 at Amneal Pharmaceuticals, up from $3.7 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $8.0 million in Q3 2024 to a low of $2.1 million in Q1 2023.
• Historically, Amortization of Deferred Charges has averaged $4.4 million across 5 years, with a median of $3.9 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges surged 240.03% in 2024, then sank 45.5% in 2025.
• A 5-year view of Amortization of Deferred Charges shows it stood at $2.1 million in 2022, then jumped by 121.46% to $4.7 million in 2023, then surged by 46.16% to $6.8 million in 2024, then tumbled by 45.5% to $3.7 million in 2025, then grew by 4.71% to $3.9 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $3.9 million (Q1 2026), $3.7 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.